These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 32625422)

  • 1. Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia.
    ; Ockleford C; Adriaanse P; Berny P; Brock T; Duquesne S; Grilli S; Hernandez-Jerez AF; Bennekou SH; Klein M; Kuhl T; Laskowski R; Machera K; Pelkonen O; Pieper S; Smith R; Stemmer M; Sundh I; Teodorovic I; Tiktak A; Topping CJ; Wolterink G; Angeli K; Fritsche E; Hernandez-Jerez AF; Leist M; Mantovani A; Menendez P; Pelkonen O; Price A; Viviani B; Chiusolo A; Ruffo F; Terron A; Bennekou SH
    EFSA J; 2017 Mar; 15(3):e04691. PubMed ID: 32625422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.
    Pelkonen O; Bennekou SH; Crivellente F; Terron A; Hernandez AF
    Arch Toxicol; 2019 Jun; 93(6):1779-1788. PubMed ID: 31053889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
    Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
    Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.
    Terron A; Bal-Price A; Paini A; Monnet-Tschudi F; Bennekou SH; ; Leist M; Schildknecht S
    Arch Toxicol; 2018 Jan; 92(1):41-82. PubMed ID: 29209747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
    Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
    Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.
    Pelkonen O; Terron A; Hernandez AF; Menendez P; Bennekou SH;
    Arch Toxicol; 2017 Aug; 91(8):2763-2780. PubMed ID: 28536863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An adverse outcome pathway on the disruption of retinoic acid metabolism leading to developmental craniofacial defects.
    Menegola E; Veltman CHJ; Battistoni M; Di Renzo F; Moretto A; Metruccio F; Beronius A; Zilliacus J; Kyriakopoulou K; Spyropoulou A; Machera K; van der Ven LTM; Luijten M
    Toxicology; 2021 Jun; 458():152843. PubMed ID: 34186166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular Pathway and AOP Development Using Gene Network Analysis].
    Tanabe S; Hirose A; Whelan M; Yamada T
    Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
    Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scientific Opinion of the PPR Panel on the follow-up of the findings of the External Scientific Report 'Literature review of epidemiological studies linking exposure to pesticides and health effects'.
    ; Ockleford C; Adriaanse P; Berny P; Brock T; Duquesne S; Grilli S; Hougaard S; Klein M; Kuhl T; Laskowski R; Machera K; Pelkonen O; Pieper S; Smith R; Stemmer M; Sundh I; Teodorovic I; Tiktak A; Topping CJ; Wolterink G; Bottai M; Halldorsson T; Hamey P; Rambourg MO; Tzoulaki I; Court Marques D; Crivellente F; Deluyker H; Hernandez-Jerez AF
    EFSA J; 2017 Oct; 15(10):e05007. PubMed ID: 32625302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
    Kim M; Kim SH; Choi JY; Park YJ
    Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the Biologically Plausible Taxonomic Domain of Applicability of an Adverse Outcome Pathway: A Case Study Linking Nicotinic Acetylcholine Receptor Activation to Colony Death.
    Jensen MA; Blatz DJ; LaLone CA
    Environ Toxicol Chem; 2023 Jan; 42(1):71-87. PubMed ID: 36263952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome.
    ; Hernandez-Jerez AF; Adriaanse P; Aldrich A; Berny P; Coja T; Duquesne S; Focks A; Millet M; Pelkonen O; Pieper S; Tiktak A; Topping CJ; Widenfalk A; Wilks M; Wolterink G; Angeli K; Recordati C; Van Durseen M; Aiassa E; Lanzoni A; Lostia A; Martino L; Guajardo IPM; Panzarea M; Terron A; Marinovich M
    EFSA J; 2023 Feb; 21(2):e07744. PubMed ID: 36818642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse outcome pathways and linkages to transcriptomic effects relevant to ionizing radiation injury.
    Yu J; Tu W; Payne A; Rudyk C; Cuadros Sanchez S; Khilji S; Kumarathasan P; Subedi S; Haley B; Wong A; Anghel C; Wang Y; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1789-1801. PubMed ID: 35939063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a putative adverse outcome pathway network for male rat reproductive tract abnormalities with specific considerations for the androgen sensitive window of development.
    Palermo CM; Foreman JE; Wikoff DS; Lea I
    Curr Res Toxicol; 2021; 2():254-271. PubMed ID: 34401750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic modelling of developmental neurotoxicity based on a simplified adverse outcome pathway network.
    Spînu N; Cronin MTD; Lao J; Bal-Price A; Campia I; Enoch SJ; Madden JC; Mora Lagares L; Novič M; Pamies D; Scholz S; Villeneuve DL; Worth AP
    Comput Toxicol; 2022 Feb; 21():100206. PubMed ID: 35211661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of an Adverse Outcome Pathway Network by Bayesian Regression and Bayesian Network Modeling.
    Moe SJ; Wolf R; Xie L; Landis WG; Kotamäki N; Tollefsen KE
    Integr Environ Assess Manag; 2021 Jan; 17(1):147-164. PubMed ID: 32965776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.
    Sachana M; Rolaki A; Bal-Price A
    Toxicol Appl Pharmacol; 2018 Sep; 354():153-175. PubMed ID: 29524501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.